文献速递呼吸衰竭与机械通气儿科与产科急症重症综合管理与镇静镇痛

阿托品联合丙泊酚与阿托品联合阿曲库铵及舒芬太尼对新生儿非紧急插管氧饱和度下降的影响:一项随机临床试验

Effect of Atropine With Propofol vs Atropine With Atracurium and Sufentanil on Oxygen Desaturation in Neonates Requiring Nonemergency Intubation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01
一句话结论新生儿非紧急经鼻插管前,阿托品-丙泊酚与阿托品-阿曲库铵-舒芬太尼两组 prolonged desaturation 发生率无显著差异(59.6% vs 65.9%),但研究可能把握度不足。

这项多中心、双盲随机临床试验在法国6个NICU纳入173例需非紧急插管的新生儿(平均胎龄30.6周,平均出生体重1502 g),比较阿托品-丙泊酚与阿托品-阿曲库铵-舒芬太尼预给药后经鼻气管插管期间 prolonged desaturation(SpO2<80%持续>60秒)的发生率。主要结局两组无显著差异:阿托品-丙泊酚组59.6% vs 阿托品-阿曲库铵-舒芬太尼组65.9%(校正RD -6.4,95%CI -21.0至8.1,P=0.38)。阿托品-丙泊酚组操作时间较长(校正RD 1.7分钟,95%CI 0.1-3.3,P=0.04),镇静质量优良率较低(51.7% vs 92.6%,P<0.001),但呼吸恢复时间较短(中位14分钟 vs 33分钟,P=0.002),肢体活动恢复时间较短(中位18分钟 vs 36分钟,P=0.003),插管后60分钟内SpO2保持更好(时间×治疗交互P=0.02)。作者结论认为两组 prolonged desaturation 频率无显著差异,但研究可能把握度不足,可能需要进一步研究。

要点

  • 在需非紧急经鼻插管的新生儿中,阿托品-丙泊酚组 prolonged desaturation(SpO2<80%持续>60秒)发生率为59.6%(53/89),阿托品-阿曲库铵-舒芬太尼组为65.9%(54/82),校正RD -6.4(95%CI -21.0至8.1,P=0.38),无显著差异。
  • 阿托品-丙泊酚组操作时间较阿托品-阿曲库铵-舒芬太尼组长(校正RD 1.7分钟,95%CI 0.1-3.3,P=0.04)。
  • 阿托品-丙泊酚组镇静质量优良率较低:51.7%(45/87) vs 92.6%(75/81),P<0.001。
  • 阿托品-丙泊酚组呼吸恢复时间较短(中位14分钟,IQR 8-34 vs 33分钟,IQR 15-56,P=0.002),肢体活动恢复时间较短(中位18分钟,IQR 10-43 vs 36分钟,IQR 19-65,P=0.003)。
  • 随机化后7天内头颅超声显示颅内出血恶化(任何或增加的脑室内出血):阿托品-丙泊酚组20.6% vs 阿托品-阿曲库铵-舒芬太尼组17.6%(校正RD 1.2,95%CI -13.1至15.5,P=0.87);严重不良事件发生率分别为11%和20%。

适用人群与场景

  • 法国6个NICU中需非紧急经鼻气管插管的新生儿,平均胎龄30.6周,平均出生体重1502 g,共173例(阿托品-丙泊酚组89例,阿托品-阿曲库铵-舒芬太尼组82例)。

处置流程与药物剂量

  • 阿托品-丙泊酚组:插管前给予阿托品联合丙泊酚预给药。
  • 阿托品-阿曲库铵-舒芬太尼组:插管前给予阿托品联合阿曲库铵及舒芬太尼预给药。

研究设计与关键结果

  • 多中心、双盲、随机临床试验(2012-2016年),纳入173例需非紧急插管的新生儿,随机分为阿托品-丙泊酚组(89例)和阿托品-阿曲库铵-舒芬太尼组(82例)。
  • 主要结局 prolonged desaturation(SpO2<80%持续>60秒):阿托品-丙泊酚组59.6%(53/89) vs 阿托品-阿曲库铵-舒芬太尼组65.9%(54/82),校正RD -6.4(95%CI -21.0至8.1,P=0.38)。
  • 操作时间:阿托品-丙泊酚组较阿托品-阿曲库铵-舒芬太尼组长,校正RD 1.7分钟(95%CI 0.1-3.3,P=0.04)。
  • 镇静质量优良率:阿托品-丙泊酚组51.7%(45/87) vs 阿托品-阿曲库铵-舒芬太尼组92.6%(75/81),P<0.001。
  • 呼吸恢复时间中位数:阿托品-丙泊酚组14分钟(IQR 8-34) vs 阿托品-阿曲库铵-舒芬太尼组33分钟(IQR 15-56),P=0.002;肢体活动恢复时间中位数:18分钟(IQR 10-43) vs 36分钟(IQR 19-65),P=0.003。
  • 插管后60分钟内SpO2保持:阿托品-丙泊酚组显著优于阿托品-阿曲库铵-舒芬太尼组(时间×治疗交互P=0.02)。
  • 随机化后7天内头颅超声显示颅内出血恶化(任何或增加的脑室内出血):阿托品-丙泊酚组20.6% vs 阿托品-阿曲库铵-舒芬太尼组17.6%,校正RD 1.2(95%CI -13.1至15.5,P=0.87)。
  • 严重不良事件:阿托品-丙泊酚组11% vs 阿托品-阿曲库铵-舒芬太尼组20%。

证据类型、等级与局限

  • 证据类型:多中心、双盲、随机临床试验。
  • 研究因研究试剂盒过期和缺乏资金而中断。
  • 作者结论指出研究可能把握度不足,无法检测出临床重要差异,可能需要进一步研究。

对床旁实践的改变

  • 作者结论认为,在需非紧急经鼻插管的新生儿中,阿托品联合丙泊酚与阿托品联合阿曲库铵及舒芬太尼的 prolonged desaturation 频率无显著差异;但研究可能把握度不足,可能需要进一步研究。
  • 阿托品-丙泊酚组镇静质量优良率较低(51.7% vs 92.6%),操作时间较长(校正RD 1.7分钟),但呼吸和肢体活动恢复较快。

指南或共识出处

  • 临床试验注册:ClinicalTrials.gov Identifier: NCT01490580;EudraCT number: 2009-014885-25。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Propofol or a combination of a synthetic opioid and muscle relaxant are both recommended for premedication before neonatal intubation but have yet to be compared.

OBJECTIVE: To compare prolonged desaturation during neonatal nasotracheal intubation after premedication with atropine-propofol vs atropine-atracurium-sufentanil treatment.

DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, randomized clinical trial (2012-2016) in 6 NICUs in France that included 173 neonates requiring nonemergency intubation. The study was interrupted due to expired study kits and lack of funding.

INTERVENTIONS: Eighty-nine participants were randomly assigned to the atropine-propofol group and 82 to the atropine-atracurium-sufentanil group before nasotracheal intubation.

MAIN OUTCOMES AND MEASURES: The primary outcome was prolonged desaturation (Spo2 <80% lasting > 60 seconds), using intention-to-treat analysis using mixed models. Secondary outcomes assessed the characteristics of the procedure and its tolerance.

RESULTS: Of 173 neonates randomized (mean gestational age, 30.6 weeks; mean birth weight, 1502 g; 71 girls), 171 (99%) completed the trial. Of 89 infants, 53 (59.6%) in the atropine-propofol group vs 54 of 82 (65.9%) in the atropine-atracurium-sufentanil group achieved the primary outcome (adjusted RD, -6.4; 95% CI, -21.0 to 8.1; P = .38). The atropine-propofol group had a longer mean procedure duration than did the atropine-atracurium-sufentanil group (adjusted RD, 1.7 minutes; 95% CI, 0.1-3.3 minutes; P = .04); a less frequent excellent quality of sedation rate, 51.7% (45 of 87) vs 92.6% (75 of 81; P < .001); a shorter median time to respiratory recovery, 14 minutes (IQR, 8-34 minutes) vs 33 minutes (IQR, 15-56 minutes; P = .002), and shorter median time to limb movement recovery, 18 minutes (IQR, 10-43 minutes) vs 36 minutes (IQR, 19-65 minutes; P = .003). In the 60 minutes after inclusion, Spo2 was preserved significantly better in the atropine-propofol group (time × treatment interaction P = .02). Of the atropine-propofol group 20.6% had head ultrasound scans that showed worsening intracranial hemorrhaging (any or increased intraventricular hemorrhage) in the 7 days after randomization vs 17.6% in the atropine-atracurium-sufentanil group (adjusted RD, 1.2; 95% CI, -13.1 to 15.5, P = .87). Severe adverse events occurred in 11% of the atropine-propofol group and in 20% of the atropine-atracurium-sufentanil group.

CONCLUSIONS AND RELEVANCE: Among neonates undergoing nonemergency nasotracheal intubation, the frequency of prolonged desaturation did not differ significantly between atropine used with propofol or atropine used with atracurium and sufentanil. However, the study may have been underpowered to detect a clinically important difference, and further research may be warranted.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01490580, EudraCT number: 2009-014885-25.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Durrmeyer X, Breinig S, Claris O, et al. Effect of Atropine With Propofol vs Atropine With Atracurium and Sufentanil on Oxygen Desaturation in Neonates Requiring Nonemergency Intubation: A Randomized Clinical Trial. JAMA. 2018. PMID: 29715354. doi:10.1001/jama.2018.3708

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。